In vitro antifungal resistance in Candida albicans from HIV-infected patients with and without oral candidosis;Resistencia in vitro a los antifungicos en Candida albicans de pacientes infectados por el VIH con y sin candidosis oral

Revista Iberoamericana de Micologia

Volumn 16, Issue 4, 1999, Pages 194-197

  Salobreña, Alejandro Ceballos ^a,e   Gaitán Cepeda, Luis A ^b   Cañada, Francisco Orihuela ^c   Barrionuevo, Delfina Olea ^c   García, Laura Ceballos ^a   Quindós, Guillermo ^d  

^a UNIVERSITY OF GRANADA   (Spain)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^d Facultad de Medicina y Odontologia   (Spain)

^e NONE   (Spain)

Author keywords

AIDS; Antifungal drugs; Candida; Fluconazole; Resistance

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; NYSTATIN;

ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; DRUG EFFICACY; DRUG SENSITIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; THRUSH;

EID: 0033373468     PISSN: 11301406     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Klein, RS, Harris CA, Small, CB, Moll B, Lesser M, Friedlan GH. Oral candidosis in high-risk patients as the initial manifestation of the acquired inmunodeficiency syndrome. N Engl J Med 1984; 311:354.
2. Plettenberg A, Reisinger E, Lenzer U, et al. Oral candidosis in HIV-infected patients. Prognostic value and correlation with immunological parameters. Mycoses 1990; 33: 421.
3. Dodd CL, Greenspan D, Katz MH, et al. Oral candidosis in VIH infection: Pseudomembranous and erythematous candidosis show similar rates of progression to AIDS. AIDS 1991, 5. 1339-1343.
4. Katz MH, Greenspan D, Westenhause J, et al. Progression to AIDS in HIV-infected homosexual and bisexual men with hairy leukoplakia and oral candidosis. AIDS 1992; 6: 95-100.
5. Smith DE, Gazzaard BG. Fluconazole versus ketoconazole in oropharyngeal candidosis in AIDS. Lancet 1989; 1:1131.
6. Hay RJ Overview of studies of fluconazol in oropharyngeal candidosis Rev Infect Dis 1990; 12 (Suppl): S334-S337.
7. Chaves JP, Cajot A, Bille J, Glauser MP. Single-doses therapy for oral candidosis with fluconazol in HIV-infected adults: A pilot study. J Infect Dis 1989, 159: 806-807.
8. Leen CLS, Dunbar EM, Ellis ME, Mandal BK. Once-weekly fluconazole to prevent recurrence of oropharyngeal candidosis in patients with AIDS and AIDS-related complex: A double-blind placebo-controlled study. J Infect Dis 1990; 21: 55-60.
9. Greenspan D. Treatment of candidosis in HIV infection. Oral Surg Oral Med Oral Pathol 1994; 78. 211-215.
10. Diz P, Ocampo A, Miralles C, Otero Y, Iglesias Y, Martínez C. Candidosis oroesofágica resistente al fluconazol en pacientes con SIDA. Enferm Infecc Microbiol Clin 1993; 11: 36-39.
11. Corzo Delgado JE, Lozano de León F, Aretio Najarro R, Martin Mazuelos E. Resistencia progresiva al fluconazol en un paciente con infección por VIH y candidosis orofaríngea recurrente. Med Clin (Bare) 1994; 10 639.
12. Heinic GS, Stevens DA, Greenspan D, et al. Fluconazole-resistant Candida in AIDS patients Report of two cases. Oral Surg Oral Med Oral Pathol 1993, 76. 711-715.
13. Quindós G, Pontón J. Candidiasis de la cavidad oral: Etiologia, patogenia y diagnóstico de laboratono. Med Oral 1996; 1: 85-95.
14. Barturen B, Bikandi J, San Millán R, et al. Variability in expression of antigens responsible for serotype specificity in Candida albicans. Microbiology 1995; 141: 1535-1543.
15. Casals JB. Tablet sensitivity testing of pathogenic fungi. J Clin Patrol 1979; 32: 719-722.
16. Casals JB, Pringler N. Antibacterial/antifungal sensitivity testing using NeoSensitabs (9th Ed). Taastrup, Denmark; Rosco Diagnostica, 1991.
17. Quindós G, San Millán R, Burgos A, et al. Evaluatión de la sensibilidad a los antifúngicos de aislamientos clínicos de los serotipos A y B de Candida albicans mediante el método ATB Fungus. Enferm Infecc Microbiol Clin 1995; 13: 209-212
18. Still JM, Law EJ, Belcher KE, Spencer SA. A comparison of susceptibility to five antifungal agents of yeast culture from burn patients. Burn 1995;21:167-170.
19. Maenza JR, Merz WG, Romagnoli MJ, Keruly JC, Moore RD, Gallant JE. Infection due to fluconazole-resistant Candida in patients with AIDS: prevalence and microbiology. Clin Infect Dis 1997;24:28-34.
20. Revankar SG, Kirkpatrick WR, McAtee RK, et al. Detection and significance of fluconazole resistance in oropharyngeal candidosis in human immunodeficiency virus-infected patients. J Infect Dis. 1996;174:821-827.
21. Drobacheff C, Manteaux A, Millon L, Reboux G, Barale T, Laurent R. Candidoses oropharyngees resistantes au fluconazole chez des malades infectes par le VIH. Ann Dermatol Venereol 1996;123.85-89.
22. Chryssanthou E, Torssannder J, Petrini B. Oral Candida albicans isolates with reduced susceptibility to fluconazole in Swedish HIV-infected patients Scand J Infect Dis 1995; 27:391-395
23. Johnson EM, Warnock DW, Luker J, Porter SR, Scully C. Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis. J Antimicrobial Chemother 1995;35: 103-114.
24. Maenza JR, Keruly JC, Moore RD, Chaisson RE, Merz WG, Gallant JE. Risk factors for fluconazole-resistant candidosis in human immunodeficiency virus-infected patients. J Infect Dis 1996; 173:219-225.
25. Ruhnke M, Eigler A, Engelmann E, Geiseler B, Trautmann M. Correlation between antifungal susceptibility testing of Candida isolates from patients with HIV infection and clinical results after treatmentwith fluconazole. Infection 1994; 22:132-136.
26. Carrillo-Munoz AJ, Abarca L, Quindós G, et al. Multicenter evaluation of Neo-Sensitabs, a standardized diffusion method for yeast susceptibility testing. Rev Iberoam Micol 1999, 16: 92-96.
27. Pemán J, Cantón E, Orero A, et al. Actividad in vitro de fluconazol sobre Candida albicans aisladas de hemocultivo. Rev Esp Quimioter 1998; 11: 339-343.
28. Tumbarello M, Caldarpla G, Tacconelli E, et al Analysis of the risk factors associated with the emergence of azole resistant oral candidosis in the course of HIV infection. J Antimicrobial Chemother 1996; 38:691-699.
29. Johnson EM, Davey KG, Szekely A, Warnock DW Itraconazole suceptibilities of fluconazole susceptible and resistant isolate of five Candida species. J Antimicrob Chemother 1995; 36:787-793.
30. Cartledge JD, Midgley J, Gazzard BG. Non-albicans oral candidosis in HIV-positive patients. J Antimicrob Chemother 1999; 43 419-422.
31. Shadomy S, Shadomy HJ. Comparative in vitro antifungal susceptibility studies with 30 serotpes A and B isolates of Candida albicans. Diagn Microbiol Infect Dis 1991;14:21-22.
32. Burgos A, Bikandi J, Fernández-Rodríguez M, Pontón J, Cisterna R, Quindós G. Correlacion entre los serotipos A y B de Candida albicans y su sensibilidad a AMB y 5-fluorocitosina. Rev Esp Quimioter 1992; 5:79-85.
33. Weber S, Polak A: Susceptibility of yeasts isolates from defined German patient groups to 5-fluorocytosine. Mycoses 1992;35:163-171.
34. Mendoza M, Russian E, Villanueva E, de Torres DE, de Albornoz MB. Sensibilidad de los serotipos A y B de Candida albicans y de otras levaduras del género Candida frente a diferentes azoles. Rev Iberoam Micol 1994; 11-74-76.
35. Imbert-Bernard C, Valentin A, Reynes J, Maillè M, Bastide JM. Relationship between fluconazole sensivity of Candida albicans isolates from HIV positive patients and serotype, adherence and CD4+ lymphocyte count Eur J Clin Microbiol Infect Dis 1994;13:711-716.